Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

LYTENAVA (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in th ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Adding bevacizumab to first-line chemotherapy for stage III or IV ovarian cancer shows limited benefit in real-world practice, with improved time to next treatment and a trend toward longer ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...